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Abstract 
Polypill is a medication designed for preventing heart attacks through a 
combination of drugs. Current formulations contain blood pressure-lowering drugs and 
others, such statins or acetylsalicylic acid. These drugs exhibit different physical 
chemical features, and consequently different release kinetics. Therefore, the 
concentration in plasma of some of them after the release process can be out of the 
therapeutic range. This paper investigates a new methodology for the control dosage of 
a polypill recently reported containing hydrochlorothiazide, amlodipine, losartan and 
simvastatin in a 12.5/2.5/25/40 weight ratio. The procedure is based on Mesoporous 
Silica Nanoparticles (MSN) with MCM-41 structure (MSN-41) used as carrier, aimed to 
control release of the four drugs included in the polypill. In vitro release data were 
obtained by HPLC and the curves adjusted with a kinetic model. To explain the release 
results, a molecular model was built to determine the drug-matrix interactions, and 
quantum mechanical calculations were performed to obtain the electrostatic properties 
of each drug. Amlodipine, losartan and simvastatin were released from the polypill-
MSN-41 system in a controlled way. This would be a favourable behaviour when used 
clinically because avoid too quick pressure decrease. However, the diuretic 
hydrochlorothiazide was quickly released from our system in the first minutes, as is 
needed in hypertensive urgencies. In addition, an increase in the stability of amlodipine 
and hydrochlorothiazide occurred in the polypill-MSN-41 system. Therefore, the new 
way of polypill dosage proposed can result in a safer and effective treatment. 
 
Keywords: Polypill, MCM-41 nanoparticles, antihypertensive drugs, cholesterol 
lowering, diuretic. 
 
Chemical compounds studied in this article 
Hydrochlorothiazide (PubChem CID: 3639); Amlodipine besylate (PubChem CID: 
60496); Losartan potassium (PubChem CID: 11751549); Simvastatin (PubChem CID: 
54454). 
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Abbreviations 
MSN, mesoporous silica nanoparticles; MSN-41, mesoporous silica nanoparticles with 
MCM-41 structure; MCM-41, Mobil composition of matter #41; MCM-41s, Mobil 
composition of matter #41 simplified molecular model; CVD, cardiovascular diseases; 
ESC, European Society of Cardiology; HTZ, hydrochlorothiazide; AML, amlodipine; 
LS, losartan; SV, simvastatin; EtOH, ethanol; BET, Brunauer, Emmett and Teller 
method; BJH, Barret-Joyner-Halenda equation; PSA, polar surface area; DM, dipole 
moment;  ADME, absorption, distribution, metabolism, and excretion.  
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1. Introduction 
Cardiovascular diseases (CVD) are the leading cause of death worldwide 
(Castelli et al., 1986; Gordon et al., 1977; Kannel and McGee, 1979; Mitchell et al., 
2010; Wilson et al., 1998). Hypertension is an important risk factor for CVD. Thus, in 
those patients already having a cardiovascular problem, hypertension can intensify the 
damage (Collins et al., 1990; Ford et al., 2007; MacMahon et al., 1990). Current 
hypertension therapies display two key problems. First, the majority of hypertensive 
treatments need to take daily several drugs (Chobanian et al., 2003; D'Amico et al., 
1998; James et al., 2014). Therefore, if the patient could forget to take some of the 
doses, decreasing the safety and increasing the side effects of hypertension. Second, too 
quick or too slow decreases in blood pressure produce is undesirable. Thus, an 
excessively rapid decrease may result in hypoperfusion of central nervous system with 
can yield to stroke, paraplegia, blindness or death. On the other hand, a very slow 
decrease is ineffective in hypertensive emergencies. Due to these facts, the maximum 
recommended blood pressure drop by 25% within the first two hours of treatment to 
reach 160/100 mmHg after six hours and then to the normal blood pressure levels in the 
following hours or days.  
To avoid possible inadvertences of the patient in taking medication doses, the 
multi-target drugs design proposes a systemic solution, safer and with lower side effects. 
Thus, medications containing several active components in a single dose (Bender et al., 
2006; Bolognesi, 2013; Petrelli and Valabrega, 2009) that for hypertension treatment is 
called polypill (Lonn et al., 2010; Sleight et al., 2006; Study, 2009). For instance, 
Laboratorios Ferrer (Spain) commercialized Sincronium
®
 and Trinomia
®
 polypill 
containing acetylsalicylic acid to prevent heart attacks, ramipril, an angiotensin-
converting enzyme inhibitor, and simvastatin or atorvastatin, as cholesterol lowering 
drugs. To reach the suitable blood pressure reduction rate, an effective controlled 
release of the drugs is required, which seems unlikely in the polypill currently 
commercialized with a conventional formulation. Thus, new research approaches are 
required in this field. In this sense, MSN-41was investigated as effective carrier for the 
controlled local release of individual active ingredients (Colilla et al., 2013; Knežević et 
al., 2013; Ruiz-Hernandez et al., 2011; Slowing et al., 2008; Tang et al., 2012; Vallet-
Regí et al., 2007; Vallet-Regi et al., 2001) but not for a polypill.  
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On the other hand, several hypertension guidelines recommend the inclusion in 
the treatment of a diuretic like hydrochlorothiazide (HTZ) e.g. European Society of 
Cardiology guidelines (ESC, June, 2016). In this regards, the combination of HZT and 
amlodipine (AML), a calcium channel blocker, with an angiotensin inhibitor, such as 
benazepril, ramipril or losartan (LS), is very effective to decrease the rate of 
cardiovascular events (Jamerson et al., 2008). Moreover, if the polypill containing a 
cholesterol lowering drug, it can be reduced by 80% the risk of CVD in patients with 
vascular disease (Chrysant and Chrysant, 2014; Exaire-Murad et al., 2015; Gadepalli et 
al., 2014; Katsiki et al., 2013; Wald and Law, 2003; Yusuf, 2002). Likewise, in a 
prevention trial of a polypill composed by AML, LS, HTZ, and simvastatin (SV), the 
mean systolic blood pressure was reduced by 12%, the diastolic blood pressure by 11%, 
and low-density lipoprotein (LDL) cholesterol by 39% (Wald et al., 2012). 
In the present work, we investigated, for the first time, the capability of a 
nanocarrier, based on MSN-41 silica nanoparticles, to host and release the four active 
components: HTZ, AML, LS and SV in 12.5/2.5/25/40 wt-ratio, contained in a polypill 
previously reported (Wald et al., 2012) according with the National Center of 
Biotechnology Information (NCBI). The objective was to reach a controlled release and 
a higher stability of the drugs to improve the traditional pharmaceutical formulation. For 
this purpose, analytical methods, molecular modelling and docking analysis were used 
as described elsewhere (Doadrio et al., 2010; Doadrio et al., 2014).  
 
2. Experimental 
2.1. Synthesis of MSN-41 mesoporous material 
Synthesis of MSN-41 with hexagonal pore arrangement, was performed by sol-
gel in the presence of structure directing agents and following a modified Stöber method 
(Stöber et al., 1968). Hence, to a 1L round-bottom flask, 1g of cetyltrimethyl-
ammonium bromide (CTAB, Sigma-Aldrich, Spain) as a structure-directing agent, 480 
mL of H2O (Milli-Q) and 3.5 mL of NaOH (2 M) were added. The mixture was heated 
at 80 ºC and stirred at 600 rpm. When the reaction mixture was stabilized at 80 ºC, 5 
mL of tetraethyl-orthosilicate (TEOS, Sigma-Aldrich, Spain) were added dropwise at 
0.33 mL/min. The suspension obtained was stirred further 2 h at 80 ºC. After filtration 
and washing with water and ethanol, the surfactant was removed by extraction with a 
NH4NO3 (Sigma-Aldrich, Spain) solution (10 mg/mL) in ethanol (EtOH) 95%. Finally, 
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the product was filtered and washed 3 times with 100 mL of H2O and with 50 mL of 
EtOH and dried under vacuum at 40 ºC. 
2.2. Drug-MSN-41 samples loading 
We prepared five different drug-MSN-41 samples. Samples 1 to 4 are the result 
of loading each drug in MSN-41. Sample 1 (HZT-MSN-41) was hydrochlorothiazide 
(99.25% purity)-MSN-41; sample 2 (AML-MSN-41) was amlodipine besylate (100% 
purity)-MSN-41; sample 3 (LS-MSN-41) was losartan potassium (99.80% purity)–
MSN-41 and sample 4 (SV-MSN-41) was simvastatin (100% purity)-MSN-41. Sample 
5 was the result of the polypill containing the four component simultaneously loaded in 
MSN-41 (polypill-MSN-41). Polypill was prepared using a mixture of HTZ, AML 
besylate, potassium LS and SV in a 12.5/2.5/25/40 weight ratio. Normon Laboratories, 
Madrid, Spain, supplied all these products. 
Samples were prepared dissolving: HTZ, 50 mg; AML, 10 mg; LS 100 mg and 
SV 160 mg (separately or together in the polypill) in 20 mL EtOH. Thereafter, 400 mg 
of MSN-41 were added with stirring for 24 h at room temperature for loading. After 
filtration, samples were dried in a vacuum oven at 20 ºC for 24 h.  
The loading process was always performed following the protocol described, 
which guaranteed its reproducibility. Furthermore, measurements were performed in 
triplicate and the indicated values correspond to the average of three measurements. 
The concentration of drug adsorbed in each MSN-41 sample (Ca) was obtained 
by the equation:  
Ca= Ci-Cr                 (1) 
where Ci is the initial concentration before loading i.e. HTZ, 2.5; AML, 0.5; LS 5 and 
SV 8 in mg/mL and Cr is the concentration analysed by HPLC in the residue of the 
drugs adsorption on MSN-41. From these data, was estimated the % of adsorption for 
each drug.  
2.3. HPLC method 
RP-HPLC (Reversed Phase High Performance Liquid Chromatography) 
measurements were performed with a liquid chromatographic system equipped with a 
Waters Alliance 2695 separation module (Waters, Milford, Massachusetts, USA), a 
variable-wavelength diode array detector Waters 2996 and controlled by Millennium 32 
software. A Zorbax Eclipse XDB-C-18 reversed-phase column (5 μm, 4.6 x 150 mm), 
supplied by Agilent Technologies, USA, was employed operating at 40 ºC. The mobile 
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phase was acetonitrile/Sörensen buffer at pH 3.5 (v/v) in a concentration gradient 
showed in Table 1. The flow rate was 1 mL/min. The effluent was monitored at 254 nm 
for HTZ and at 234 nm for LS, AML and SV. The injection volume was 10 μL. In these 
conditions, the retention times (tr) for HTZ, AML, LS and SV were 1.79, 2.61, 4.45 and 
15.8 min, respectively. Four-calibration curves using the standard drugs loaded in 
MSN-41 were plotted using concentrations in methanol for each drug of 0.1, 0.5, 1 and 
1.5 mg/mL.  
2.4. Characterization 
Samples were characterized by powder X-ray diffraction (XRD), Fourier 
transform infrared (FTIR) spectroscopy and N2 adsorption-desorption. The XRD 
patterns were obtained in a Philips X´Pert MPD (Cu Kα radiation) diffractometer. The 
diffractograms were collected in the 2 range of 0.6–10º with a step size of 0.02º. FTIR 
spectra were recorded with a Nicolet Nexus spectrophotometer in the range of 4000–
400 cm
-1
 by using a ATR golden gate accesory. The surface area and pore size of the 
materials were determined by N2 adsorption using a Micromeritics ASAP 2020 
porosimeter. Previously, loaded samples were degassed at 100 ºC for 24 h under 
vacuum (1.3 Pa). The pore size distribution was calculated from adsorption branches of 
the nitrogen isotherms using the Barret-Joyner-Halenda (BJH) equation (Barrett and 
Joyner, 1951) and the BET surface area was calculated by Brunaver, Emmett and Teller 
method (Brunauer et al., 1938). Furthermore, the particle morphology was analysed by 
scanning electron microscopy (SEM) using a Hitachi S-350 JSM 6335F field emission 
microscope operated at 20 kV. Finally, high-resolution transmission electron 
microscopy (HRTEM) was carried out with a JEOL 3000 FEG electron microscope 
operating at 300 kV (Tokyo, Japan). TEM images were recorded using a CCD camera 
(MultiScan model 794, Gatan, 1024 × 1024 pixels, size 24 μm × 24 μm). 
2.5. MSN-41 samples release 
The drug-loaded MSN-41 samples (1 to 5) were soaked in 20 mL of Sörensen 
phosphate buffer at pH= 7.5 (compatible with biological pH) and maintained at 37 ºC 
with stirring for all the assay time. The drugs concentration in solution was measured by 
HPLC as described above.  
For kinetic analysis we have used the Peppas equation (Ritger and Peppas, 
1987): Mt/M=kt
n
, being Mt/M the drug-released fraction at time t and k reaction rate 
 8 
constant, to know the drugs release mechanism governed by n. Thus, a value of n = 0.5 
indicates a Fickian diffusion, while n values < 0.5 indicate the presence of other 
simultaneous processes. For n = 0.5, the Higuchi equation (Higuchi, 1963) based on the 
Fick's law can be used. However, when n is < 0.5, as it happens in this study, 
controlling release mechanisms were investigated according to non-lineal exponential 
proportional rate growth or decrease model and the best-fit curve using Origin v.9 
software (OriginLab
®
 Northampton, USA.). The kinetic model is given as:  
D(t) = A(1-e
-kct -vc
)                          (2)  
where D(t) is % of drug released for each sampling time, A is the asymptote, c and v are 
adjustment parameters, k is the kinetic constant observed and t is the time in min
-1
. The 
model, a non-lineal first-order kinetic, resulted in the most precise adjustment for this 
study.  
On the other hand, highest percentage of drug released (%Dmax) was obtained by 
the equation:  
%Dmax= Ctmax*100/Ca                (3) 
where Ctmax is the concentration of each drug measured by HPLC at tmax and Ca is 
defined by Eq. (1). The maximum times (tmax) was when the drug degradation for each 
drug started at the pH of the study (7.5). The drug degradation starts when the measured 
drug concentration decrease.  
To check that the silica dissolution do not influence the drugs stability, for each 
drug we performed a study by HPLC in identical conditions of a MSN-free system. 
Finally, the percentage of drug released at 5 min (%D5) was obtained by the 
equation:  
%D5= C5*100/Ctmax                 (4) 
where C5 is the concentration of each drug measured by HPLC at 5 min and Ctmax is 
defined by Eq. (3). The time at 5 min corresponds to the first fast desorption process 
that occurs in the drugs studied and will be described in section 3.3.1. 
2.6. Molecular modelling 
A simulated MCM-41 molecular model was generated by using the Hyperchem 
8.01 software (Hypercube, Inc. Gainesville, FL). The building unit in this model was 
the pseudo-cell, Si6O12, consisting of hexagonal arrangements of Si–O–Si units. The 
oxygen atoms saturate all the silicon atoms at the pore surface. Furthermore, hydrogen 
atoms saturate the oxygen atoms bonded to less than two silicon atoms. Therefore, all 
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the hydroxyl groups are located at the outer surface of the model. From this 2D layer 
structure, the 3D model was generated by using the built module of Hyperchem 
software. That way, 15 layers were added until reaching a model of 7.03 nm length and 
2.1 in diameter. The final structure was refined by optimization of the geometry using 
the 500 steps of Stepest-Descend and 1500 steps Polak-Ribiere conjugate gradient 
algorithms both using the MM+ force field. The minimization process concluded when 
the energy converged or when a gradient of 0.1 kcal/mol was reached. 
However, for docking calculations, the size of MCM-41 model exceeds the 
operating capability of our system. In consequence, an AM1 semi-empirical method for 
a simplified MCM-41 model of 8 layers with dimensions 2.10 nm of diameter and 3.81 
nm length (MCM-41s) was used. HTZ, AML, LS, and SV docking calculations on the 
MCM-41s model surface were carried out by using ArgusLab 4.0.1 software with a 
cubic box of 6 nm x 2.7 nm x 2.7 nm and grid resolution of 0.040 nm. The binding site 
was defined from the ligands coordinates in the MCM-41s model. Argusdock 
exhaustive search docking engine was used (Morris et al., 1998). All calculations were 
made in vacuum due to the construction of a solvent box not change substantially the 
results. Therefore, these calculations adding complexity to the system by increasing the 
calculation time. 
For electrostatic potential maps, coordinates of HTZ, AML, LS and SV drugs 
were obtained from DrugBank v. 5.0 (DrugBank, June, 2016) and treated by molecular 
dynamics simulations from Spartan´14 (Wavefunction, Inc.). Area, volume, polar 
surface area (PSA) and dipole moment (DM) of HTZ, AML, LS and SV molecules 
were also obtained, which are shown in Table 2.  
 
3. Results and discussion 
3.1. Samples characterization 
Samples as received by different experimental techniques were characterized. 
Fig. 1 shows SEM and TEM images of sample 5 after the release process. As is 
observed by SEM, the MSN-41 particles maintained their spherical shape with average 
diameter close to 150 nm in a quite homogeneous size distribution. Furthermore, the 
heterogeneities observed in TEM micrograph are indicative of the partial loss of the 2D-
hexagonal arrangement of MSN-41. This finding can be explained considering a partial 
dissolution of the silica network that would happen during the drugs loading (24 h in 
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ethanol) and the release (196 h in phosphate buffer at pH 7.5) processes. These results 
would agree with the reported in vitro degradation of mesoporous silica networks after 
being soaked by 240 h in different aqueous media (Izquierdo-Barba et al., 2010). In this 
case, the partial dissolution of the nanoparticles is not relevant for the loading and the 
final drug formulations because the time of drug degradation is lower that the 
dissolution time. In addition, the degradation times of the four drugs were identical in 
MSN-free and MSN-containing systems.    
Fig. 2 shows Low Angle-XRD patterns and N2 adsorption-desorption isotherms 
(inside) of MSN-41 and sample 5 after releasing. MSN-41 pattern shows three 
diffraction maxima at 2.05º, 3.7º and 4.3º in 2, which can be respectively indexed to 
(10), (11) and (20) reflections of a 2D hexagonal arrangement, being the unit cell 
parameter a0= 4.98 Å. For sample 5 the XRD pattern shows only a diffuse shoulder 
indicating the partial loss of mesoporous order with the simultaneous inclusion of the 
four drugs in the nanoparticles. This inclusion nearly fills the mesopores of the 
nanoparticles. In addition, the electrostatic interactions and by hydrogen bond between 
the drugs with the matrix are intense, what causes strains within pores that can deform 
the pore wall and consequently the pore shape. An analogous deformation of the 
mesopores was reported after the functionalization of a mesoporous matrix. (Doadrio et 
al., 2014). 
The isotherms shape with absence of hysteresis cycle indicates that the pores 
size is enough small to avoid the N2 molecules condensation. These are the typical 
curves of MCM-41 materials with cylindrical pores of small size. From these 
measurements was obtained a maximum in the diameter of pore (Dp) of 4.64 nm and 
BET surface area (SBET) of 1047.6 m
2
/g for MSN and 2.0 nm (Dp) and 289.5 m
2
/g 
(SBET) for polypill-MSN-41. XRD patterns and N2 adsorption-desorption isotherm 
results are consistent with the entrance of drugs into matrix mesopores. 
Finally, the FTIR characterization of MSN-41 and polypill-MSN-41 exhibited 
quite similar spectra dominated by the presence of the three bands characteristic of 
MCM-41 silica at 1050-1057 cm
-1
, 954 cm
-1
, 800-804 cm
-1
 and 439 cm
-1 
(results not 
shown). 
3.2. Samples adsorption 
The Ca values obtained for samples 1 to 4 by using Eq. (1) were: HTZ, 1.25; 
AML, 0.24; LS, 2.03 and SV, 3.9 in mg/mL, respectively and essentially the same were 
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found for sample 5. Therefore, the adsorption of drugs was close to 50%, that is, HTZ= 
500.5%, AML= 480.5%. SV= 48.80.5%, and somewhat lower for LS that was 
410.5%. 
3.3. Samples release 
As it is established, the drug released from ordered mesoporous materials such 
as MCM-41 take place through a Fickian diffusion mechanism (Vallet-Regí et al., 2007; 
Yang et al., 2012). In these cases, normally the Higuchi equation can be applied. 
However, in this study, the values of n obtained from Peppas equation were lower than 
0.5, indicating the existence of other processes that influences the drug release. For this 
reason, we used the nonlinear first order Eq. (2), which includes most of the factors 
involved in the drug release rate. This adjustment is better than those accomplished with 
the classical Higuchi equation. For example, for HTZ-MSN-41 (sample 1) with n= 0.49 
(maximum value reached for a sample), when applying Higuchi equation, the R
2
 
obtained was 0.23 while with the Eq. (2) was 0.956. Analogous results were obtained 
for the other samples with values of n lower than 0.49.  
It must be considered that in the release of a drug from a mesoporous matrix two 
stages take place. The one, a fast desorption, when the material is filling with water, 
leads to an uncontrolled drug release. The second one, which takes place when pores are 
already filled, results in a controlled drug release. The first stage mainly depends on the 
solubility of the drug in water. The second one is more complex and involves many 
factors. Among them, the electrostatic interactions, hydrogen bonds, as well as solid-
liquid diffusion, such as the area, volume, polarity (including PSA and DM), as well as 
liposolubility, percentage of ionization (pKa-pH), lipophilicity (log P), tortuosity of the 
channels, and the drug solubility (Doadrio et al., 2015). On the other hand, previous 
articles demonstrated that hydrogen bond and electrostatic forces factors could be 
critical in the release of a drug from the mesoporous matrix (Doadrio et al., 2010; 
Doadrio et al., 2014). 
3.3.1. Samples 1-4 controlled release 
First, for comparative purposes, we studied the release of HTZ, AML, LS and 
SV, independently loaded on MSN-41 (samples 1 to 4). Kinetic data, including the n 
parameter, observed kinetic constants (Kobs) and R
2
 for each drug-MSN-41 are shown in 
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Table 3. Additionally, in Table 3 shows the values obtained of %Dmax and %D5 from Eq. 
3 and Eq. 4, respectively, besides tmax. 
Considering first the kinetic rate constants (Kobs) in samples 1 to 4, respectively. 
For HTZ in sample 1, Kobs is bigger (0.51) than in the other three samples: AML in 
sample 2 (0.0016), LS in sample 3 (0.001) and SV in sample 4 (0.0044). Consequently, 
HTZ release is faster than those of other drugs. 
Moreover, the profile of the release curve for sample 1 shows a sudden release 
of HTZ in the first 5 min of assay. Analogous behavior was observed for samples 2 to 4, 
but with a slower release profile (Fig. 3). This corresponds to the first stage in the drug 
release mechanism previously mentioned. For a controlled release, the drug desorption 
rate must be constant over a period. This does not occur during the first stage of drug 
desorption, but it occurs during the second stage. Therefore, to reach a controlled 
release of a drug from MSN-41 it is necessary a relatively insignificant desorption (in 
time and weight) on the first stage. This happens for AML-MSN-41, LS-MSN-41 and 
SV-MSN-41 but not in HTZ-MSN-41. For HTZ-MSN-41, an 80.5 % was released in 
the first 5 min (%D5), while in AML-MSN-41, LS-MSN-41 and SV-MSN-41, the 
release process is controlled from the outset, with %D5 values of 6.6, 3.3 and 6.0%, 
respectively. This can be explained by the different solubility of the drugs in water. That 
way, HTZ had a high desorption in the first stage, because it dissolves rapidly in water 
(722 mg/mL at 25 ºC), in contrast with AML (75 mg/mL), LS (0.8 mg/mL) and SV (< 
0.8 mg/mL) (PubChem, June, 2016). In addition, the polarity of drugs should be taken 
into account (Table 2). In this sense, a polar molecule such as HTZ should have more 
affinity for water with respect to AML, LS and SV.  
In the AML, LS and SV release the prevalent factor is log P. The most lipophilic 
molecule investigated is SV (log P= 4.7), thus is the most retained drug with respect to 
AML (log P= 3.0) and LS (log P= 4.3) (PubChem, June, 2016). However, the release 
rate of AML and LS are similar. This confirms that there is not a rapid desorption of 
AML, LS and SV, because the release process is controlled from the beginning. In these 
cases, other parameters exert their action from the outset influencing the control of 
delivery from MSN-41.  
Another factor that should influence the release of AML, LS and SV on MSN-41 
is pKa. The pKa values for these drugs are AML, 8.79; LS, 5.5 and SV, 14.9 (PubChem, 
June, 2016). For these values, the % ionization obtained by Henderson-Hasselbalch 
equation was: 4.89 for AML, 99.0 for LS and only 4.10
-6
 for SV. These data suppose 
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that SV will be primarily in its neutral form, while LS will be ionized. Besides, SV is 
the least soluble, which agree with a neutral form. LS is also very sparingly soluble but 
it is ionized, which increase its solubility and AML is more soluble than those two. The 
lipophilicity of the SV makes to be less retained in the mesoporous matrix than AML 
and LS. 
3.3.2. Polypill-MSN-41 controlled release 
Then, we have studied our polypill-MSN-41 (sample 5) and the kinetic results 
are shown in Table 4. In this sample, there are interactions among the components of 
the polypill. This fact was demonstrated from docking calculations in the simplified 
MCM-41s model (Fig. 4a) where interactions among four-drug molecules were 
observed (Fig. 4b). Furthermore, molecular modeling calculations showed that drug 
molecules exhibit negatively charged areas and other areas of positive charge, so 
London electrostatic interactions between them are possible (Fig. 4c). In addition, all 
molecules have the possibility to join by hydrogen bonds between them and with the 
matrix. 
All these facts influence the desorption results of the drugs. Thus, there is a 
major release of the total amount of the polypill components. For instance, HTZ it 
released 14.7 times more in the polypill-MSN-41 (%Dmax= 9.88) than in HTZ-MSN-41 
(0.67). The same happens for AML, 1.72 times (22-12%); LS, 1.28 times (1.1-0.85%) 
and SV, 3.68 times (0.14-0.038%).  
On the other hand, release profiles do not change substantially (Fig. 3) in the 
polypill-MSN-41 (sample 5), with a rapid desorption on the first 5 min for HTZ (%D5, 
82.9) similar to HTZ-MSN (sample 1), but with better control for AML (2.6-6.6%), LS 
(1.6-3.3%) and SV (3.5-6.0%). These facts indicate a controlled release in the polypill-
MSN-41 for AML, LS and SV, but not for HTZ, as it happened in sample 1 (HTZ-
MSN-41). However, this behavior would be beneficial for HTZ, a drug used in 
hypertensive emergencies. In addition, Kobs values of HTZ, AML, LS and SV in sample 
5, i.e. 0.49, 0.0011, 0.0022 and 0.0017, respectively (Table 4), are consistent to those 
obtained with the drugs separately loaded, although LS is higher while SV is lower 
(Table 3).  
Consequently, all these findings clearly evidence that there are many factors 
related to drug adsorption/resorption processes. As a result, the proposed model in this 
paper based on a non-linear first-order kinetic was the appropriate. 
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3.3.3. Drug stability 
 The polypill-MSN-41system has improved the drug stability. Thus, in all cases, 
the time of drug stability is larger than required for its metabolization (1 to 5 h). 
Furthermore, HTZ, AML, LS and SV are stable in our system until 48, 98, 170 and 48 h, 
respectively. These values are higher than those of the drug half-life, which range: 5.6-
14.8 h for HTZ, 30-50 h for AML, 2 h for LS and 3 h for SV (DrugBank, June, 2016). 
Moreover, HTZ and AML are higher stable than when each drug was loaded separately 
in MSN-41 matrix. Thus, HTZ in sample 1 only was stable until 32 h and AML until 48 
h. These results can be attributed to the interaction observed by docking between AML 
and HTZ. The increase in the drug stability will be especially important in the 
pharmaceutical application of AML, LS and SV because the antihypertensive and 
cholesterol lowering medication requires a chronic treatment. Identical degradation 
times for the four drugs were obtained in MSN-free polypill systems.   
 
3.4. Molecular modelling 
In order to understand the release mechanism of polypill-MSN-41 a new MCM-
41 model was built with a hexagonal channel of the MCM-41 matrix of greater length. 
This new structure is formed by 2D hexagonal mesopore where the walls are composed 
by amorphous silica. Fig. 5 shows the model obtained by molecular modelling. Models 
of silica mesopores specifically for MCM-41, have been designed by our group 
(Doadrio et al., 2010; Doadrio et al., 2014) and other authors (Coasne and Ugliengo, 
2012; He and Seaton, 2003; Ugliengo et al., 2008; Williams et al., 2016; Zhuo et al., 
2008). However, these MCM-41 models were built with the purpose of introducing a 
single molecule into the matrix or without and has not been tested with four molecules 
at a time. Besides, the small length of the channels previously used prevented a realistic 
view about the molecules and molecules-matrix interactions in four drugs models. In 
this way, the new MCM-41 model designed with larger pore diameter and length is 
more realistic allowing introduce four drug.  
Docking studies confirm that the four molecules studied can penetrate by size 
and electrostatic charge in the tested MCM-41 model and that HTZ and AML can join 
together by electrostatic forces (Fig. 4). Another possibility is that the molecules of 
other components of the polypill also join each other. This is in agreement with LS 
being retained significantly lower in the polypill-MSN-41 (sample 5) and the SV being 
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more retained. The interaction energies of the four molecules with the matrix calculated 
by molecular docking were: AML: -3.6 Kcal/mol; LS: -4.17 Kcal/mol; SV: -4.24 
Kcal/mol and HTZ: -4.18 Kcal/mol. Moreover, docking showed the charge 
compatibility between the four-drug and with the mesoporous silica matrix. On the 
other hand, docking calculations did not allow us to calculate the interactions between 
the drug molecules. From the values of the dipolar moments showed on Table 2 it can 
be deduced that HTZ is the most polar of the four components of the polypill with a 
dipolar 9.15 D. On the contrary, AML show the lower dipolar moment with a value of 
1.87 D. Moreover, the right part of Figure 4 shows the images the electrostatic potential 
of the four molecules. As it is observed, AML shows a strongly positive region, not 
present in the other molecules. This region can strongly bond with the highly negative 
region of HTZ and would explain the interaction between both molecules.   
The polypill-MSN-41 system could be administered as coated tablets or by 
parenteral way; the last one not affected by the intestinal absorption. Moreover, to 
determine the pharmacologically active doses of drugs released and the ADME 
(absorption, distribution, metabolism, and excretion) process, in vivo pharmacokinetic 
and pharmacological studies will be needed.  
 
4. Conclusions 
This study has shown that MSN-41 mesoporous silica nanoparticles, can be an 
effective carrier for a polypill dosage. This carrier, allows an effective controlled 
release of AML, LS and SV and a quick release of HTZ. A controlled release of AML 
and LS ensures the proper metabolization in antihypertensive treatment, discarding the 
adverse effects of a too higher or too lower dose. Furthermore, the controlled release of 
SV is suitable for long-term treatments. Moreover, the quick release of HTZ from 
polypill-MSN-41 will be optimum for hypertensive emergencies treatment. 
In addition, MSN-41 carrier increase the stability of the four components of the 
polypill investigated improving their half-life and metabolism time. Moreover, HTZ 
and AML are more stable in the polypill that when were released independently from 
MSN-41 because a bond between both molecules by electrostatic forces is established. 
The MCM-41molecular model built in this study confirmed the release results 
obtained by HPLC. 
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Therefore, a new approach for the dosage of a polypill has been opened in this 
study that can result in a safer and effective treatment. 
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Table 1. HPLC concentration gradient in acetonitrile (A)/Sörensen buffer at pH 3.5 (B).  
 
Step Time (min) %A %B 
1 0 40 60 
2 5 40 60 
3 5.1 60 40 
4 25 60 40 
5 25.1 40 60 
  
 
Table 2. Area, volume, PSA and DM for MCM-41 model and HTZ, AML, LS and SV 
from molecular modelling obtained by Spartan´14 software.  
 
 Area (Å
2
) Volume (Å
3
) PSA (Å
2
) DM (debye) 
MCM-41 model 3131.9 3042.1 2074.6 95.69  
HZT 246.4 216.3 119.9 9.15  
AML 432.3 401.6 81.4 1.67  
LS 442.6 416.3 81.1 3.31  
SV 468.2 452.8 59.1 3.10 
 
 
Table 3. Kinetic data of 1 to 4 samples: HZT-MSN-41, AML-MSN-41, LS-MSN-41, 
SV-MSN-41. 
 
 HZT-MSN-41 AML-MSN-41 LS-MSN-41 SV-MSN-41 
n 0.49 0.41 0.31 0.23 
Kobs (min
-1
) 0.51 0.0016 0.001 0.0044 
R
2
 0.956 0.981 0.981 0.957 
tmax (min) 1920 2880 10200 2880 
%Dmax 0.67 12.78 0.85 0.038 
%D5 80.5 6.6 3.3 6.0 
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Table 4. Kinetic data of the components of polypill-MSN-41 (sample 5). 
 
 HTZ AML LS SV 
n 0.03 0.40 0.27 0.47 
Kobs (min
-1
)  0.49 0.0011 0.0022 0.0017 
R
2
 0.958 0.995 0.983 0.966 
tmax (min) 2880 5880 10200 2880 
%Dmax 9.88 22.0 1.10 0.14 
%D5 82.9 2.6 1.6 3.5 
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FIGURE CAPTIONS 
Fig 1. Morphology of MSN nanoparticles in sample 5 after releasing observed by SEM 
and TEM.  
Fig 2. XRD patterns of MSN-41 and polypill-MSN-41 (sample 5). Inside: Adsorption-
desorption isotherms of MSN-41 and polypill-MSN-41. Dp=diameter of pore; SBET= 
BET surface area. 
Fig 3. Best-fit curves from polypill-MSN-41 (sample 5) for each component and drugs-
MSN-41 (samples 1 to 4) in comparative way. Percent release (%D(t)) was calculated 
for each drug loaded in MSN-41. For each drug and sample, the times indicated in the 
figure mean the starting of the drug degradation that supposed the end of the HPLC 
analysis. 
Fig 4. a) Molecular modelling distances of MCM-41s model (3.81x2.1 nm). b) Docking 
results showing HTZ (white), AML (yellow), LS (blue), SV (pink) and MCM-41s. c) 
Electrostatic potential maps in a simulation way of HTZ, AML, LS and SV molecules 
on MCM-41s from Spartan´14 software. The color criteria represent negative charges in 
red and positive charges in blue.  
Fig 5. Molecular modelling distances of MCM-41 new model (7.03x2.1 nm). Left: in 
length. Right: in diameter. 
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